Multiple sclerosis: latest news - GoINPHARMA
Saturday, 15 December 2018 - 21:45

Multiple sclerosis

Novartis introduces therapy arsenal for multiple sclerosis

Novartis has introduced today at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently being held in Berlin, data related to a clinical trial assessing Gilenya (fingolimod), an oral therapy for MS, in addition…

Roche granted approval for ocrelizumab (multiple sclerosis) in Europe

Roche has announced that the European Commission has granted a marketing authorization to ocrelizumab, for the treatment of patients with relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. The European Commission has considered the positive results from the…

Multiple sclerosis and vitamin D: new data supporting the link

The review Neurology has published the results from an extensive study confirming that Vitamin D deficiency can be a risk factor for the onset of multiple sclerosis. The researchers analyzed a sample of healthy individuals, measuring their vitamin D levels…

New multiple sclerosis therapy by Merck approved in Europe

The German-language press today gave extensive coverage to the marketing approval in Europe to Cladribine, a brand-new multiple sclerosis therapy developed by Germany-based Merck KGaA. Cladribine is the first oral treatment ever commercialized for multiple sclerosis, a condition affecting 2.3…

Roche presents new data from trial with Ocrelizumab for multiple sclerosis

Switzerland-based multinational Roche announced that it will present new post-hoc analyses from the Phase III clinical trial program assessing ocrelizumab in people with relapsing and primary progressive forms of multiple sclerosis (RMS and PPMS) at the Congress of the European…

New study on alemtuzumab’s efficacy in multiple sclerosis treatment

The journal Neurology has published a study showing that patients with multiple sclerosis (MS), treated with alemtuzumab (Lemtrada) can experience a significant improvement of the disease-associated disabilities. The study was conducted on 628 patients, 426 of which treated with alemtuzumab…